CL2007002107A1 - Compuestos derivados de bencil piperidin-1-il amina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hiperlipidemia, arterioesclerosis, ateroesclerosis, vasculopatia periferica, dislipidemia, entre otras enfermedades. - Google Patents
Compuestos derivados de bencil piperidin-1-il amina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hiperlipidemia, arterioesclerosis, ateroesclerosis, vasculopatia periferica, dislipidemia, entre otras enfermedades.Info
- Publication number
- CL2007002107A1 CL2007002107A1 CL200702107A CL2007002107A CL2007002107A1 CL 2007002107 A1 CL2007002107 A1 CL 2007002107A1 CL 200702107 A CL200702107 A CL 200702107A CL 2007002107 A CL2007002107 A CL 2007002107A CL 2007002107 A1 CL2007002107 A1 CL 2007002107A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- arterioesclerosis
- aterosclerosis
- bencil
- amina
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06117541 | 2006-07-20 | ||
US88705807P | 2007-01-29 | 2007-01-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2007002107A1 true CL2007002107A1 (es) | 2008-06-06 |
Family
ID=38695303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL200702107A CL2007002107A1 (es) | 2006-07-20 | 2007-07-19 | Compuestos derivados de bencil piperidin-1-il amina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hiperlipidemia, arterioesclerosis, ateroesclerosis, vasculopatia periferica, dislipidemia, entre otras enfermedades. |
Country Status (23)
Country | Link |
---|---|
US (1) | US20090286790A1 (es) |
EP (1) | EP2049517B1 (es) |
JP (1) | JP5042311B2 (es) |
KR (1) | KR101149274B1 (es) |
AR (1) | AR061926A1 (es) |
AU (1) | AU2007276433B2 (es) |
CA (1) | CA2657258A1 (es) |
CL (1) | CL2007002107A1 (es) |
CO (1) | CO6150155A2 (es) |
CR (1) | CR10478A (es) |
EC (1) | ECSP099078A (es) |
GT (1) | GT200900010A (es) |
HK (1) | HK1132262A1 (es) |
HR (1) | HRP20140183T1 (es) |
IL (1) | IL195792A (es) |
MA (1) | MA30638B1 (es) |
MX (1) | MX2009000646A (es) |
NO (1) | NO342106B1 (es) |
PE (1) | PE20080404A1 (es) |
PL (1) | PL2049517T3 (es) |
TN (1) | TN2009000012A1 (es) |
TW (1) | TWI387593B (es) |
WO (1) | WO2008009435A1 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2696016A1 (en) * | 2007-07-13 | 2009-01-22 | Addex Pharma S.A. | Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EP2463282B1 (en) | 2007-11-05 | 2013-08-07 | Novartis AG | 4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis |
CA2707651A1 (en) * | 2007-12-03 | 2009-06-11 | Novartis Ag | 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis |
MX2010006045A (es) | 2007-12-12 | 2010-06-23 | Amgen Inc | Inhibidores de transportador de glicina-1. |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
SG186493A1 (en) | 2010-07-09 | 2013-01-30 | Daiichi Sankyo Co Ltd | Substituted pyridine compound |
US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
ES2683350T3 (es) | 2011-07-08 | 2018-09-26 | Novartis Ag | Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos |
TWI570118B (zh) | 2012-01-06 | 2017-02-11 | 第一三共股份有限公司 | 經取代之吡啶化合物的酸加成鹽 |
UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
CU24330B1 (es) | 2013-02-14 | 2018-03-13 | Novartis Ag | Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral) |
JP2014172851A (ja) * | 2013-03-07 | 2014-09-22 | Chiba Univ | ピラゾール誘導体の製造方法およびイソオキサゾール誘導体の製造方法 |
EA201690282A1 (ru) | 2013-07-25 | 2016-09-30 | Новартис Аг | Биоконъюгаты синтетических апелиновых полипептидов |
JP6501775B2 (ja) | 2013-07-25 | 2019-04-17 | ノバルティス アーゲー | 心不全治療用の環状ポリペプチド |
JP6402907B2 (ja) * | 2014-09-24 | 2018-10-10 | Jnc株式会社 | ピペリジン誘導体、液晶組成物および液晶表示素子 |
MA41580A (fr) | 2015-01-23 | 2017-11-29 | Novartis Ag | Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée |
UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
WO2020180959A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
PE20221010A1 (es) | 2019-08-14 | 2022-06-15 | Incyte Corp | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2 |
CN110508018B (zh) * | 2019-09-03 | 2022-02-25 | 中国石油大学(华东) | 生产聚甲氧基二甲醚的装置及方法 |
JP2022551668A (ja) | 2019-10-11 | 2022-12-12 | インサイト・コーポレイション | Cdk2阻害剤としての二環式アミン |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
US4889861A (en) | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
US4617307A (en) | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
RU2086544C1 (ru) | 1991-06-13 | 1997-08-10 | Хоффманн-Ля Рош АГ | Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина |
MY110227A (en) * | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
US5508272A (en) | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
TW313568B (es) | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
US6140342A (en) | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
WO2000018724A1 (en) | 1998-09-25 | 2000-04-06 | Monsanto Company | (R)-CHIRAL HALOGENATED 1-SUBSTITUTEDAMINO-(n+1)-ALKANOLS USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY |
CN104383554B (zh) | 2002-09-06 | 2018-06-08 | 天蓝制药公司 | 用于传递治疗剂的以环糊精为基础的聚合物 |
JP2007519605A (ja) | 2004-01-30 | 2007-07-19 | 日本たばこ産業株式会社 | 食欲抑制薬 |
MY150958A (en) | 2005-06-16 | 2014-03-31 | Astrazeneca Ab | Compounds for the treatment of multi-drug resistant bacterial infections |
CA2707651A1 (en) * | 2007-12-03 | 2009-06-11 | Novartis Ag | 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis |
-
2007
- 2007-07-18 JP JP2009519868A patent/JP5042311B2/ja not_active Expired - Fee Related
- 2007-07-18 US US12/374,463 patent/US20090286790A1/en not_active Abandoned
- 2007-07-18 WO PCT/EP2007/006384 patent/WO2008009435A1/en active Application Filing
- 2007-07-18 CA CA002657258A patent/CA2657258A1/en not_active Abandoned
- 2007-07-18 AU AU2007276433A patent/AU2007276433B2/en not_active Ceased
- 2007-07-18 MX MX2009000646A patent/MX2009000646A/es active IP Right Grant
- 2007-07-18 KR KR1020097001089A patent/KR101149274B1/ko not_active IP Right Cessation
- 2007-07-18 EP EP07786158.1A patent/EP2049517B1/en active Active
- 2007-07-18 PL PL07786158T patent/PL2049517T3/pl unknown
- 2007-07-18 AR ARP070103209A patent/AR061926A1/es unknown
- 2007-07-19 TW TW096126359A patent/TWI387593B/zh not_active IP Right Cessation
- 2007-07-19 CL CL200702107A patent/CL2007002107A1/es unknown
- 2007-07-19 PE PE2007000936A patent/PE20080404A1/es not_active Application Discontinuation
-
2008
- 2008-12-02 CR CR10478A patent/CR10478A/es unknown
- 2008-12-08 IL IL195792A patent/IL195792A/en active IP Right Grant
-
2009
- 2009-01-16 GT GT200900010A patent/GT200900010A/es unknown
- 2009-01-16 TN TN2009000012A patent/TN2009000012A1/fr unknown
- 2009-01-19 EC EC2009009078A patent/ECSP099078A/es unknown
- 2009-01-20 CO CO09004534A patent/CO6150155A2/es unknown
- 2009-02-11 MA MA31630A patent/MA30638B1/fr unknown
- 2009-02-17 NO NO20090756A patent/NO342106B1/no not_active IP Right Cessation
- 2009-10-20 HK HK09109684.3A patent/HK1132262A1/xx not_active IP Right Cessation
-
2014
- 2014-02-27 HR HRP20140183TT patent/HRP20140183T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
JP5042311B2 (ja) | 2012-10-03 |
AU2007276433A1 (en) | 2008-01-24 |
EP2049517A1 (en) | 2009-04-22 |
AR061926A1 (es) | 2008-10-01 |
PL2049517T3 (pl) | 2014-06-30 |
IL195792A0 (en) | 2009-09-01 |
MA30638B1 (fr) | 2009-08-03 |
EP2049517B1 (en) | 2013-11-27 |
WO2008009435A1 (en) | 2008-01-24 |
TW200813022A (en) | 2008-03-16 |
KR20090031579A (ko) | 2009-03-26 |
US20090286790A1 (en) | 2009-11-19 |
MX2009000646A (es) | 2009-01-29 |
KR101149274B1 (ko) | 2012-05-29 |
IL195792A (en) | 2013-07-31 |
GT200900010A (es) | 2009-06-24 |
CA2657258A1 (en) | 2008-01-24 |
HK1132262A1 (en) | 2010-02-19 |
HRP20140183T1 (hr) | 2014-04-11 |
AU2007276433B2 (en) | 2011-06-16 |
CO6150155A2 (es) | 2010-04-20 |
NO342106B1 (no) | 2018-03-26 |
ECSP099078A (es) | 2009-02-27 |
NO20090756L (no) | 2009-04-14 |
CR10478A (es) | 2009-02-02 |
TN2009000012A1 (en) | 2010-08-19 |
JP2009543827A (ja) | 2009-12-10 |
TWI387593B (zh) | 2013-03-01 |
PE20080404A1 (es) | 2008-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2007002107A1 (es) | Compuestos derivados de bencil piperidin-1-il amina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hiperlipidemia, arterioesclerosis, ateroesclerosis, vasculopatia periferica, dislipidemia, entre otras enfermedades. | |
CL2007001325A1 (es) | Compuestos derivados de biciclos, inhibidores de cept; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hiperlipidemia, arterioesclerosis, entre otras enfermedades. | |
CL2008002319A1 (es) | Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. | |
CL2007003226A1 (es) | Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer. | |
CL2008001372A1 (es) | Compuestos derivados de pirazol sustituidos con heteroarilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar trastornos hiperproliferativos y enfermedades relacionadas con angiogenesis. | |
CL2008001983A1 (es) | Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades vasculares, shock septico, lesiones isquemicas, neurotoxicidad, shock hemorragico, infecciones virales, entre otras. | |
CL2008000197A1 (es) | Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. | |
CL2007003470A1 (es) | Compuestos derivados de urea; composicion farmaceutica que comprende a dichos compuestos; y su uso como antibacterianos. | |
CL2008000789A1 (es) | Compuestos derivados de adenina; composicion farmaceutica que comprende a dichos compuestos, utiles para tratar enfermedades alergicas, virales o cancer, entre otras. | |
CL2008000754A1 (es) | Compuesto derivado de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso para tratar cancer y trastornos hiperproliferativos. | |
CL2007003212A1 (es) | Compuestos derivados de imidazopirazinas, inhibidores de proteina quinasa; composicion farmaceutica que los comprende; y su uso para tratar cancer. | |
CL2007003713A1 (es) | Compuestos derivados de 2-amino-4-oxo-3,5-dihidroimidazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar o prevenir una patologia relacionada con abeta, tales como alzheimer, parkinson, sindrome de down, entre otras | |
CL2008000369A1 (es) | Compuestos derivados de piridopirimidinonas; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar dolor, depresion, enfermedades cardiovasculares, enfermedades respiratorias y enfermedades psiquiatricas. | |
CL2007001451A1 (es) | Compuestos derivados de [1,2,3]-tiazol-4-ilmetoxilo, agonista del receptor farnesoide x (fxr); composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar dislipidemia y enfermedades relacionadas. | |
CL2008000703A1 (es) | Compuestos derivados de pirimidinas sustituidas; procedimiento para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar transtornos hematologicos. | |
CL2009000882A1 (es) | Un compuesto n-(4-cloro-3-(piridin-2-il)fenil)-4-(2-hidroxi-2-metilpropilsulfonil)-2-metilbenzamida, inhibidor de la via de señalización hedgehog; composición farmacéutica que comprende a dicho compuesto; y su uso para tratar el cancer. | |
CL2007003797A1 (es) | Compuestos derivados de pirrolo piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la enfermedad de alzheimer, parkinson, cancer, entre otras enfermedades. | |
CL2007003232A1 (es) | Compuestos derivados de 5-hidroximetil oxazolidin-2-ona; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar y prevenir infecciones bacterianas. | |
CL2008000784A1 (es) | Compuestos amino-5-[-4-(diflourometoxi) fenil sustituido]-5-fenilmidazolona, inhibidores de b-secretasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar alzheimer, deterioro cognitivo, sindrome de down, disminucion co | |
CL2007002446A1 (es) | Compuestos derivados de morfolino pirimidina; composicion farmaceutica; y su uso para preparar un medicamento para producir un efecto antiproliferante. | |
CL2008001002A1 (es) | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. | |
BRPI0814593A2 (pt) | Composto, composição farmacêutica que o contém e uso do composto. | |
CL2008000403A1 (es) | Compuestos derivados de pentafluorotiobenzamido-acetonitrilo; composicion farmaceutica; y uso para tratar una infestacion por parasitos. | |
CL2007003832A1 (es) | Compuestos derivados de azaespiro; procedimiento de preparacion; composicion farmaceutica; y su uso para prevenir y tratar ansiedad, trastornos depresivos, entre otras enfermedades. | |
CL2008000794A1 (es) | Compuestos derivados de biarilo y heteroarilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno de hierro. |